The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This is the company’s first partnership arrangement in China
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Subscribe To Our Newsletter & Stay Updated
